EL7.AI
StocksMedium•14 September 2026•
1 min read

Corbus Pharmaceuticals Reports Positive Phase 1b Results for Obesity Drug

Key Facts

1Corbus Pharmaceuticals announced positive topline data from the Phase 1b CANYON-1 study of CRB-913 for obesity treatment.
2The drug demonstrated a 5% mean weight loss at a 60 mg dose after 12 weeks and was generally well tolerated.

Amid the intensifying race to develop oral alternatives to traditional obesity treatments, Corbus Pharmaceuticals has announced positive topline data from its Phase 1b CANYON-1 study of CRB-913. According to reports, the drug candidate demonstrated a 5% mean weight loss at a 60 mg dose after 12 weeks of treatment. The study indicated that the oral candidate was generally well tolerated, supporting its potential as a new class of non-incretin obesity medicines.

These results bolster the company's competitive position in the high-growth obesity market, targeting patients who may not tolerate or respond to existing GLP-1 therapies. Per analyst data, treatment discontinuation rates due to adverse events ranged from 3.1% to 13.1%, which is in line with currently approved oral treatments. The company aims to distinguish CRB-913 through its oral delivery and distinct mechanism of action compared to established injectables.

Regarding market performance, CRBP stock stood at $8.12 at the close of September 11, 2026, having reached a day high of $8.49. Investors should look forward to a late-breaking presentation of the full CANYON-1 data at ObesityWeek® 2026, scheduled for November 14–17. This upcoming catalyst will be critical for assessing the drug's regulatory timeline and its potential for accelerated approval pathways.